CHMP Moves Jaypirca One Step Closer to EU Approval for CLL
The Committee for Medicinal Products for Human Use (CHMP) has recommended Jaypirca for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy. Unlike previous treatment approaches, the recommendation applies regardless of prior BTK inhibitor use, potentially expanding patient eligibility across the European Union. Eli Lilly described the opinion as an important regulatory milestone ahead of the European Commission’s final approval decision.
BRUIN Phase 3 Results Pushed Jaypirca Toward Regulatory Success
The recommendation was based on results from the Phase 3 BRUIN CLL-313 trial. According to Professor Paolo Ghia, data from both BRUIN CLL-313 and BRUIN CLL-314 showed that pirtobrutinib delivered meaningful clinical benefit together with a favorable tolerability profile across multiple treatment settings. He added that the CHMP opinion brings the therapy closer to broader patient access throughout Europe.
Why Jaypirca Could Reshape Earlier CLL Treatment Across Europe
Lilly Oncology President Jacob Van Naarden said the company believes Jaypirca could become an important option for newly diagnosed patients as well as individuals who have not previously received a BTK inhibitor. Because many patients now receive fewer treatment lines during their lifetime, earlier treatment decisions have become increasingly important. As a result, this recommendation represents more than a product milestone and highlights the evolving regulatory approach to CLL treatment.
A 45% Risk Reduction Added New Momentum to Jaypirca’s EU Journey
Earlier this month, Eli Lilly announced positive results from the Phase 3 BRUIN CLL-322 trial, which evaluated Jaypirca in combination with venetoclax and rituximab for patients with previously treated CLL or small lymphocytic lymphoma (SLL). According to the company, the combination reduced the risk of disease progression or death by 45%. These findings further expanded the clinical evidence supporting Jaypirca and strengthened its potential role across different stages of the CLL treatment pathway.
All Eyes Turn to the European Commission After CHMP’s Decision
The CHMP recommendation does not represent final approval. The European Commission will now review the opinion before making its marketing authorization decision. If approved, Jaypirca could become available across the European Union for adults with CLL regardless of prior BTK inhibitor treatment, marking another significant step in Europe’s evolving regulatory strategy for blood cancer therapies.
The CHMP recommendation for Jaypirca reflects how regulatory decisions increasingly rely on robust clinical evidence and well-governed quality systems. If your organization is preparing for evolving regulatory expectations, Zamann Pharma Support’s Quality Management System service helps build compliant, inspection-ready processes that support sustainable GMP operations.
Source: Pharmexec.Com